There is new hope for those affected by breast cancer. The FDA has approved a drug for late-stage breast cancer.
Friday, the first patient in Austin to receive the drug will begin treatment with Kadcyla, the new drug developed to treat patients with HER2-positive late stage or Metastatic breast cancer.
HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.
Cancer specialist and oncologist Dr. Jason Kaplan says the new drug is practice changing and will save lives.
"It can allow the chemotherapy to be directly delivered into the tumor cells bypassing the normal tissue thereby sparing the normal tissue of some of the toxicity of chemotherapy," Dr. Kaplan said.
Dr. Kaplan adds that HER2-positive breast cancer makes up about 20 percent of breast cancer cases.